financetom
Business
financetom
/
Business
/
Hotel chain Hyatt bets on India's population boom to fuel growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hotel chain Hyatt bets on India's population boom to fuel growth
Apr 10, 2025 5:58 PM

(Reuters) - Hyatt Hotels ( H ) is betting on India's rising population and consumer spending power to help the U.S. hotel chain keep up revenue growth in the double-digit percentage range in the Asian country this financial year, an executive said.

Global hotel operators have been building diverse property portfolios in the world's most populous country, targeting its more affluent consumers, whose appetite for domestic travel has been strong since the relaxation of COVID curbs.

Hyatt, which has roughly 325 of its more than 1,400 hotels in Asia Pacific, is looking to expand in the region, and "India is a big part of that," Carina Chorengel, a senior executive, told Reuters on Wednesday.

Hyatt said it plans to open six hotels in India, home to roughly 1.4 billion people, this year including in smaller cities from northern Ghaziabad to southern Kochi.

Within five years, it is planning to double its hotel count in India to 100, Hyatt said.

Many global brands, from fast-food restaurant operators to apparel sellers, have been downplaying the recent slowdown in Indian consumer spending to double down on the country to tap its growing middle class in the longer term.

India's growing population, rapid urbanization with more people moving to its cities and their desire to travel more are the key reasons Hyatt is focusing more on India, Chorengel said.

The hotel chain would also post revenue growth in the double-digit percentage range in India in fiscal 2026, after recording similar growth in previous years, said Sunjae Sharma, managing director of India and Southwest Asia at Hyatt.

Late last year, rival Hilton Worldwide said it plans to quadruple the number of hotel rooms in its India pipeline in five years.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's Tabcorp appoints former AFL boss Gillon McLachlan as CEO
Australia's Tabcorp appoints former AFL boss Gillon McLachlan as CEO
Jun 16, 2024
(Reuters) - Australian gambling services firm Tabcorp Holdings ( TABCF ) on Monday appointed former Australian Football League (AFL) boss Gillon McLachlan as its chief executive and managing director. The appointment comes months after former chief Adam Rytenskild resigned over allegedly using offensive and inappropriate language at the workplace and as the firm navigates a strategic transformation amid heightened competition...
Currencies consolidate as dollar steadies, euro hangs near one-month low
Currencies consolidate as dollar steadies, euro hangs near one-month low
Jun 16, 2024
TOKYO (Reuters) -The dollar was firm on Monday as the euro hovered near a more than one-month low amid political turmoil in Europe, while investors awaited fresh clues on the strength of the U.S. economy. Investors have been contemplating the risk of a budget crisis at the heart of the euro area, as far right and leftist parties gain momentum...
UBS to book $0.9 billion provision linked to inherited Greensill funds
UBS to book $0.9 billion provision linked to inherited Greensill funds
Jun 16, 2024
ZURICH (Reuters) - UBS expects to record a provision of around $0.9 billion, the Swiss bank said on Monday, in connection to Credit Suisse's funds linked to collapsed supply chain financing firm Greensill Capital. The Credit Suisse Supply Chain Finance Funds have made an offer to redeem fund units, UBS said. Fund investors who choose to accept the offer will...
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
Jun 16, 2024
June 17 (Reuters) - AstraZeneca's ( AZN ) blockbuster cancer drug Imfinzi combined with chemotherapy has been approved in the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient, the drugmaker said. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved